Please login to the form below

Not currently logged in
Email:
Password:

Istodax

This page shows the latest Istodax news and features for those working in and with pharma, biotech and healthcare.

Novartis gets OK for panobinostat in myeloma

Novartis gets OK for panobinostat in myeloma

followed three years later by Celgene's rival CTCL therapy Istodax (romidepsin). .

Latest news

  • Celgene's cancer drug promising in small HIV study Celgene's cancer drug promising in small HIV study

    Lymphoma therapy Istodax shows potential in treating the virus. A cancer drug sold by Celgene could be used to drive HIV from hidden reservoirs within the body so the virus becomes ... Study leader Ole Schmeltz Søgaard from Aarhus University in Denmark

  • FDA gives early green light to Spectrum’s lymphoma drug FDA gives early green light to Spectrum’s lymphoma drug

    Spectrum's Folotyn anti-folate drug (pralatrexate) was cleared in 2009 for use in patients with relapsed or refractory PTCL while Celgene got the nod for its HDAC inhibitor Istodax (romidepsin) ... Spectrum claims Beleodaq has a broader mechanism than

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....